1) Post-β-lactamase inhibitor effect
β内酰胺抑制剂后效应
2) post β-lactamase inhibitor effect (PLIE)
β-内酰胺酶抑制剂后效应
3) β-lactamase inhibitor
β-内酰胺酶抑制剂
1.
Characterization of β-lactamase inhibitors reduced susceptibility in clinical isolates of Escherichia coli and Klebsiella pneumoniae;
临床产酶大肠埃希氏菌、肺炎克雷伯氏菌对β-内酰胺酶抑制剂敏感性降低的特征研究
2.
Sulbactam sodium,a β-lactamase inhibitor,was synthesized from 6-aminopenicillanic acid by diazotization,bromination,oxidation,reduction and salt formation under suitable conditions.
以6-氨基青霉烷酸为起始原料,经重氮化、溴化、氧化、还原、成盐制备β-内酰胺酶抑制剂舒巴坦钠,精选出合适的工艺条件,提高了成品的收率,使总收率达72。
3.
Tazobactam, a β-lactamase inhibitor, was synthesized from benzhydryl 2β-chloromethyl 2α-methylpenam-3α-carboxylate by azidation, oxidation, cyclization with acetylene to form triazole, and then deprotection with m-cresol in an overall yield of 28%.
以 2 β-氯甲基青霉烷酸二苯甲酯为起始原料 ,经叠氮化、氧化后 ,用乙炔成三唑环 ,再用间甲苯酚脱羧基保护基制得新型 β-内酰胺酶抑制剂他唑巴坦 ,总收率 2 8%。
4) Inhibitor-resistant β-lactamase
耐酶抑制剂β-内酰胺酶
1.
Inhibitor-resistant β-lactamases;
耐酶抑制剂β-内酰胺酶的研究现状
5) β-lactamase inhibitors
β-内酰胺酶抑制剂
1.
OBJECTIVE: To analyze the condition of compound preparations of β-lactamase inhibitors in clinical application in our hospital during the period 2002～2004.
目的:分析本院2002年~2004年β-内酰胺酶抑制剂复方制剂临床用药情况。
2.
OBJECTIVE To analyze the clinical application of compound preparations ofβ-lactamase inhibitors in our hospital during the period of 2001~2005.
目的分析本院2001年~2005年β-内酰胺酶抑制剂复合制剂临床用药情况。
补充资料：β-内酰胺酶抑制剂
分子式：C8H8KNO5
分子量：暂无
CAS号：61177-45-5
性质：暂无
制备方法：暂无
用途：β-内酰胺酶抑制剂。
分子量：暂无
CAS号：61177-45-5
性质：暂无
制备方法：暂无
用途：β-内酰胺酶抑制剂。
说明：补充资料仅用于学习参考，请勿用于其它任何用途。
参考词条